PDA Advanced Parenteral Therapeutics & Quality Summit 2026
The PDA Advanced Parenteral Therapeutics & Quality Summit 2026 focuses on the rapidly evolving landscape of advanced therapies, bringing together regulators, industry leaders, and technical experts to address the unique challenges of cell and gene therapies (ATMPs). The program explores how regulatory expectations, manufacturing strategies, and quality systems are adapting to support these complex and high‑growth modalities.
Across two days, participants will gain insight into critical areas such as contamination control strategies (CCS), Annex 1 implementation, sterility assurance, and quality risk management, alongside perspectives on Taiwan’s growing role in global biopharmaceutical supply.
The summit is designed to provide practical, forward-looking discussions and valuable connections for professionals navigating the future of advanced therapeutic manufacturing.
#PDA #APAC #Quality
Follow us on LinkedIn
